keyword
MENU ▼
Read by QxMD icon Read
search

Biodegradable polymer stent

keyword
https://www.readbyqxmd.com/read/27875036/drug-loaded-nanoparticle-coating-on-totally-bioresorbable-plla-stents-to-prevent-in-stent-restenosis
#1
Jian Zhao, Zhichao Mo, Fangfang Guo, Donglu Shi, Qian Qian Han, Qing Liu
Biodegradable polymer poly (dl-lactide) (PDLLA) has been used as drug coating material for drug-eluting stents due to its excellent biocompatibility and sustained drug release ability. However, the uniform thin layer drug eluting coating on a stent not only inhibits the blood vessel's smooth muscle cell overgrowth but also delay the endotheliation process which is often associated with the occurrence of acute thrombosis. Therefore, in this study, we developed a novel coating method using PDLLA nanoparticles (NPs) as a coating to overcome this issue...
November 22, 2016: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
https://www.readbyqxmd.com/read/27872316/outcomes-of-acute-myocardial-infarction-patients-implanted-with-biodegradable-polymer-biolimus-eluting-stents-versus-new-generation-durable-polymer-drug-eluting-stents-a-retrospective-analysis
#2
Jeong Cheon Choe, Kwang Soo Cha, Hye Yoon Jang, Jong Hyun Choi, Bo Won Kim, Jinhee Ahn, Jin Sup Park, Hye Won Lee, Jun-Hyok Oh, Jung Hyun Choi, Han Cheol Lee, Taek Jong Hong, Youngkeun Ahn, Myung Ho Jeong
We compared outcomes between biodegradable polymer biolimus-eluting stent (BP-BES) and new-generation durable polymer drug-eluting stent (DP-DES) implantations in patients with acute myocardial infarction (MI). Among 13472 patients with acute MI in a nationwide registry, 557 (64.8%) were in the BP-BES and 303 (35.2%) in the new-generation DP-DES group following coronary reperfusion. The occurrence of major adverse cardiac events (MACE; death, MI, revascularization) and stent thrombosis was compared. Major adverse cardiac events occurred in 53 (6...
November 20, 2016: Angiology
https://www.readbyqxmd.com/read/27866136/biodegradable-polymer-based-argatroban-eluting-cobalt-chromium-stent-jf-04-for-treatment-of-native-coronary-lesions-final-results-of-the-first-in-man-study-and-lessons-learned
#3
Yoshihiro Morino, Tetsuya Tobaru, Satoshi Yasuda, Kazuaki Kataoka, Kengo Tanabe, Atsushi Hirohata, Ken Kozuma, Takeshi Kimura
AIMS: The aim of the study was to investigate the six-month angiographic and nine-month clinical follow-up outcomes in a first-in-man study using the biodegradable polymer-based cobalt-chromium argatroban-eluting stent (JF-04) for treatment of native coronary atherosclerotic lesions. METHODS AND RESULTS: A total of 31 patients with either stable or unstable angina, or silent myocardial ischaemia, exhibiting de novo coronary lesions were enrolled at seven Japanese sites...
November 20, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27814621/drug-release-kinetics-from-a-drug-eluting-stent-with-asymmetrical-coat
#4
Haijun Zhang, Xiaodong Li, Wei Deng, Xiangfei Wang, Shenguo Wang, Junbo Ge, Egon Toft
The aim of this study was to investigate the drug release profiles of biodegradable polymer sirolimus- or paclitaxel-eluting stents with asymmetrical coating (BPSES-A or BPPES-A) both in vitro and in vivo. In vitro, the drug release profile was characterized by measuring the drug concentration by HPLC over a time-course. In vivo, a porcine aorta stenting model was employed. The results showed that the drug release rates of BPSES-A and BPPES-A were slower, more stable and less burst releasing than those of conventionally coated stents (BPSES-C and BPPES-C respectively), both in vitro and in vivo...
January 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/27806902/very-thin-strut-biodegradable-polymer-everolimus-eluting-and-sirolimus-eluting-stents-versus-durable-polymer-zotarolimus-eluting-stents-in-allcomers-with-coronary-artery-disease-bio-resort-a-three-arm-randomised-non-inferiority-trial
#5
Clemens von Birgelen, Marlies M Kok, Liefke C van der Heijden, Peter W Danse, Carl E Schotborgh, Martijn Scholte, R Melvyn Tjon Joe Gin, Samer Somi, K G van Houwelingen, M G Stoel, Frits H A F de Man, J Hans W Louwerenburg, Marc Hartmann, Paolo Zocca, Gerard C M Linssen, Job van der Palen, Carine J M Doggen, Marije M Löwik
BACKGROUND: In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers...
November 26, 2016: Lancet
https://www.readbyqxmd.com/read/27806901/biodegradable-polymer-drug-eluting-stents-non-inferiority-waiting-for-superiority
#6
Aloke V Finn, Renu Virmani
No abstract text is available yet for this article.
October 28, 2016: Lancet
https://www.readbyqxmd.com/read/27802927/biolimus-eluting-versus-everolimus-eluting-stents-in-coronary-artery-disease-a-pooled-analysis-from-the-next-and-compare-ii-randomized-trials
#7
Georgios J Vlachojanni, Serban Puricel, Masahiro Natsuaki, Takeshi Morimoto, Pieter C Smits, Taskeshi Kimura
AIMS: This study sought to investigate the safety and efficacy of the biolimus-eluting stent with biodegradable polymer (BP-BES; Nobori, Terumo) compared to the everolimus-eluting stent with durable polymer (DP-EES; Xience V or Prime, Abbott Vascular, or Promus, Boston Scientific). METHODS AND RESULTS: The all-comers NEXT and COMPARE II clinical trials randomly assigned 5942 patients to BP-BES (N=3412) or DP-EES (N=2530). We conducted a patient level pooled analysis at 3 year follow-up with specified study endpoints definite stent thrombosis (ST), the combined safety endpoint cardiac death or target vessel myocardial infarction (TV-MI), and the efficacy endpoint target lesion revascularization (TLR)...
November 2, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27792651/comparison-of-vascular-responses-following-new-generation-biodegradable-and-durable-polymer-based-drug-eluting-stent-implantation-in-an-atherosclerotic-rabbit-iliac-artery-model
#8
Gaku Nakazawa, Sho Torii, Takeshi Ijichi, Hirofumi Nagamatsu, Yohei Ohno, Fumi Kurata, Ayako Yoshikawa, Masataka Nakano, Norihiko Shinozaki, Fuminobu Yoshimachi, Yuji Ikari
BACKGROUND: Incomplete endothelialization is the primary substrate of late stent thrombosis; however, recent reports have revealed that abnormal vascular responses are also responsible for the occurrence of late stent failure. The aim of the current study was to assess vascular response following deployment of biodegradable polymer-based Synergy (Boston Scientific) and Nobori (Terumo) drug-eluting stents and the durable polymer-based Resolute Integrity stent (Medtronic) in an atherosclerotic rabbit iliac artery model...
October 19, 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27773396/one-year-outcomes-of-a-biomime%C3%A2-sirolimus-eluting-coronary-stent-system-with-a-biodegradable-polymer-in-all-comers-coronary-artery-disease-patients-the-merit-3-study
#9
Rajendra Kumar Jain, Padmanabha Chakravarthi, Rajan Shetty, Padmakumar Ramchandra, Raghava Sarma Polavarapu, Gurupreet Singh Wander, Bishav Mohan, Darshan Navinchandra Banker, Aniruddha Dharmadhikari, Shyam Sundar Bansal, Neeraj Jain, Dharmesh Solanki, Jagdish Dhakaan, Ved Prakash Sharma, Padhinhare P Mohanan, Parayaru Kottayal Ashokan, Bagur Venkat Manjunath, Narendra Hiregoudar, Chandrashekar Patil, Narasimha Balakrishnan
OBJECTIVES: The aim of the merit-3 study was to determine the safety and performance of the BioMime Sirolimus-Eluting Coronary Stent System (SES) in all-comer patients with coronary artery disease (CAD) in one-year clinical follow-up period. METHODS: The meriT-3 was a multi-centre, observational, post-marketing study conducted in 1161 patients with CAD who were implanted with BioMime SES at 15 sites in India. The primary endpoint was major adverse cardiac event (MACE) at one year defined as the composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR)...
September 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27725331/-biodegradable-catheters-and-urinary-stents-when
#10
F Soria, E Morcillo, A López de Alda, T Pastor, F M Sánchez-Margallo
One of the main wishes in the field of urinary catheters and stents is to arm them with biodegradable characteristics because we consider a failure of these devices the need for retrieval, the forgotten catheter syndrome as well as the adverse effects permanent devices cause after fulfilling their aim. The efforts focused in new designs, coatings and biomaterials aim to increase the biocompatibility of theses internal devices. Lately, there have been correct advances to answer the main challenges regarding biodegradable ureteral devices...
October 2016: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/27722631/nanoscale-patterning-of-biopolymers-for-functional-biosurfaces-and-controlled-drug-release
#11
Akshit Peer, Rabin Dhakal, Rana Biswas, Jaeyoun Kim
We compare the rates of drug release from nanopatterned and flat biodegradable polymer surfaces, and observe significantly lower release rates from the nanopatterned surfaces. Specifically, we nanopattern poly(l-lactic acid) (PLLA), a biodegradable polymer frequently used for fabricating drug-eluting coronary stents, through microtransfer molding and solvent casting and investigate the nanopattern's impact on the release of sirolimus, an immunosuppressant agent, coated on the PLLA surface using high performance liquid chromatography/mass spectrometry...
October 5, 2016: Nanoscale
https://www.readbyqxmd.com/read/27714601/intravascular-imaging-comparison-of-two-metallic-limus-eluting-stents-abluminally-coated-with-biodegradable-polymers-ivus-and-oct-results-of-the-destiny-trial
#12
J Ribamar Costa, Daniel Chamié, Alexandre A C Abizaid, Expedito Ribeiro, George C Meireles, Maurício Prudente, Carlos A Campos, Juliana P Castro, Ricardo Costa, Pedro A Lemos
We sought to compare, by means of IVUS and OCT imaging, the performance of a novel sirolimus-eluting drug-eluting stent (DES) with biodegradable polymer (Inspiron™) to the Biomatrix™ DES. From the DESTINY trial, a total of 70 randomized patients (2:1) were enrolled in the IVUS substudy (Inspiron™, n = 46; Biomatrix™: n = 20) while 25 patients were evaluated with OCT (Inspiron™, n = 19; Biomatrix™: n = 06) at 9-month follow-up. The main endpoints were % of neointimal tissue obstruction (IVUS) and neointimal stut coverage (OCT) at 9 months...
October 6, 2016: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/27665852/five-year-outcomes-of-chronic-total-occlusion-treatment-with-a-biolimus-a9-eluting-biodegradable-polymer-stent-versus-a-sirolimus-eluting-permanent-polymer-stent-in-the-leaders-all-comers-trial
#13
Matteo Ghione, Joanna J Wykrzykowska, Stephan Windecker, Patrick W Serruys, Pawel Buszman, Axel Linke, Hae Young Sohn, Roberto Corti, Diethmar Antoni, William Wijns, Rodrigo Estevez-Loureiro, Marie-Claude Morice, Gerrit-Anne Van Es, Robert Jan van Geuns, Peter Juni, Pedro Eerdmans, Ton De Vries, Stéphanie Konik, Carlo Di Mario
BACKGROUND: Few data are available on long-term follow-up of DES in the treatment of chronic total occlusion (CTO). The LEADERS CTO sub-study compared the long-term results in CTO and non-CTO lesions of a Biolimus A9™-eluting stent (BES) with a sirolimus-eluting stent (SES). METHODS: Among 1,707 patients enrolled in the prospective, multi-center, all-comers LEADERS trial, 81 with CTOs were treated with either a BES (n = 45) or a SES (n = 36). The primary endpoint was the occurrence of major adverse cardiac events (MACE): cardiac death, myocardial infarction (MI) and clinically-indicated target vessel revascularization (TVR)...
September 26, 2016: Cardiology Journal
https://www.readbyqxmd.com/read/27661023/randomized-clinical-trial-comparing-abluminal-biodegradable-polymer-sirolimus-eluting-stents-with-durable-polymer-sirolimus-eluting-stents-nine-months-angiographic-and-5-year-clinical-outcomes
#14
Haijun Zhang, Xiangfei Wang, Wei Deng, Shenguo Wang, Junbo Ge, Egon Toft
BACKGROUND: The biodegradable polymer drug-eluting stents (DES) were developed to improve vascular healing. However, further data and longer-term follow-up are needed to confirm safety and efficacy of these stents. This randomized clinical trial aimed to compare safety and efficacy of 2 sirolimus-eluting stents (SES): Cordimax-a novel abluminal biodegradable polymer SES and Cypher Select-a durable polymer SES, at 9 months angiographic and 5-year clinical follow-up. METHODS: We randomized 402 patients with coronary artery disease to percutaneous coronary intervention with Cordimax (n = 202) or Cypher select (n = 200)...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27643678/computational-and-experimental-investigation-into-mechanical-performances-of-poly-l-lactide-acid-plla-coronary-stents
#15
Qian Wang, Gang Fang, Yinghong Zhao, Guohui Wang, Tao Cai
Poly-L-lactide Acid (PLLA), as a credible biodegradable polymer-based material, can provide a promising amount of degradation time for vessel remodeling. Served as a sort of reliable intravascular implants, PLLA stents are expected to provide sufficient scaffolding to the target arteries without generating too much recoil after deployment. Besides, the stress and strain distribution should be as homogeneous as possible, and the stent conformability in fitting to the nature curvature of the vessels needs to be guaranteed...
August 31, 2016: Journal of the Mechanical Behavior of Biomedical Materials
https://www.readbyqxmd.com/read/27634137/long-term-outcomes-of-biodegradable-polymer-biolimus-eluting-stents-versus-durable-polymer-everolimus-eluting-stents-a-meta-analysis-of-randomized-controlled-trials
#16
Ryota Sakurai, Ivana Burazor, Heidi N Bonneau, Hideaki Kaneda
BACKGROUND: Both biodegradable polymer biolimus-eluting stents (BP-BES) and biocompatible durable polymer everolimus-eluting stents (DP-EES) have been developed to decrease the risk of late adverse events. However, their efficacy and safety beyond 1year after stent deployment still remain controversial. METHODS: We conducted a meta-analysis on randomized controlled trials (RCTs) comparing BP-BES with DP-EES in patients undergoing percutaneous coronary intervention in long-term follow up (beyond 1year), and compared the pooled estimates with those in mid-term follow up (within 1year)...
November 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27628493/biodegradable-polymer-drug-eluting-stents-back-to-the-future
#17
Salvatore Cassese, Erion Xhepa, Adnan Kastrati
No abstract text is available yet for this article.
September 14, 2016: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/27625144/performance-of-the-xlimus-sirolimus-eluting-coronary-stent-in-very-complex-lesions
#18
Carlo Briguori, Gabriella Visconti, Michael Donahue, Vito Di Palma, Francesca De Micco, Giuseppe Signoriello, Amelia Focaccio
INTRODUCTION: Stent delivery failure may occur especially when treating complex coronary artery stenosis. XLIMUS (CARDIONOVUM GmbH, Bonn, Germany) is a new sirolimus-eluting stent (SES) with the following features: 1) cobalt chromium stent platform, with low (73 μm) strut thickness, (2) biodegradable polymer, and 3) potent antiproliferative drug (Sirolimus). Preliminary data suggest that XLIMUS SES may be ideal for the treatment of complex lesions. METHODS: In this registry, we assessed the deliverability, safety, and efficacy of percutaneous coronary interventions (PCI) using the XLIMUS SES in patients undergoing elective PCI in native coronary vessels for complex de novo lesions, including severe calcification, severe tortuosity, and chronic total occlusion...
December 2016: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/27612817/dynamic-contact-angle-cycling-homogenizes-heterogeneous-surfaces
#19
R Belibel, C Barbaud, L Mora
In order to reduce restenosis, the necessity to develop the appropriate coating material of metallic stent is a challenge for biomedicine and scientific research over the past decade. Therefore, biodegradable copolymers of poly((R,S)-3,3 dimethylmalic acid) (PDMMLA) were prepared in order to develop a new coating exhibiting different custom groups in its side chain and being able to carry a drug. This material will be in direct contact with cells and blood. It consists of carboxylic acid and hexylic groups used for hydrophilic and hydrophobic character, respectively...
December 1, 2016: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/27608017/the-ultimaster-biodegradable-polymer-sirolimus-eluting-stent-an-updated-review-of-clinical-evidence
#20
REVIEW
Alberto Chisari, Anna Maria Pistritto, Raffaele Piccolo, Alessio La Manna, Gian Battista Danzi
The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer, sirolimus-eluting coronary stent. The high elasticity of the biodegradable-polymer (PDLLA-PCL) and the abluminal gradient coating technology are additional novel features of this coronary device. The Ultimaster DES has undergone extensive clinical evaluation in two studies: The CENTURY I and II trials...
September 6, 2016: International Journal of Molecular Sciences
keyword
keyword
58904
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"